As promised, this is the last of almost 500 regularly scheduled IBJ columns. My assistant Susan and I trashed the “fat file,” the one on issues and ideas we have maintained for the last 25 years.
Indianapolis Monthly is not abandoning print. But the 42-year-old magazine is making a serious push into digital in an effort to grow its reach—and eventually revenue.
The endowment’s assets reached $15.1 billion at the end of 2018, pushing it ahead of the Ford Foundation and the J. Paul Getty Trust, which had assets of $13.1 billion and $13.2 billion, respectively.
Under fire from politicians, patients and health care advocates over the price of insulin, Eli Lilly and Co. announced a campaign Thursday morning to raise awareness of cost-saving options for the drug.
Intelligent Fiber Network has spent the last 18 months rebranding—including a name change that telegraphs its growth plans—and ramping up its marketing.
There was no shortage of huge news stories in central Indiana this year—with Roger Penske’s purchase of the Indianapolis Motor Speedway, the launching of the Red Line and the closing of trucking giant Celadon.
There were some surprising tech developments this year in the central Indiana market. Synovia Solutions’ and Sigsters’ acquisitions come to mind. What’s not surprising is the change that continues to shape this sector. Like the evolution of technology itself, the stream of startups, pivots, mergers and acquisitions this year—like most—came fast and furious.
The deal, which is expected to close by mid-2020, will swell Elanco from the world’s fourth-largest animal health player to the second-largest, behind only New Jersey-based Zoetis.
Podcast host Mason King talks with IBJ Managing Editor Lesley Weidenbener and reporter Anthony Schoettle about Penske Corp.’s acquisition of the Indianapolis Motor Speedway, Eli Lilly and Co.’s biggest acquisition ever, trucking giant Celadon’s demise, Ambrose’s decision to pull back from the GM stamping plant site and more.
The year didn’t feature any hostile takeovers or huge disasters. But a lot of companies made big strides in 2019, including Eli Lilly and Co., Corteva and Elanco. And many rejoiced when Washington ended a 2.3% tax on thousands of medical devices.
Alimta is Lilly’s third-best-selling drug, with global sales of $2.1 billion last year. The court ruling stops a Canadian competitor from launching a generic version of the drug before its patent expires in 2022.
So many big stories of 2019—Roger Penske’s purchase of the Indianapolis Motor Speedway, big acquisitions by Eli Lilly and Co. and Elanco, the launch of the Red Line—were as much about the future as they were about the past.
The state’s lead economic development agency announced Monday that it secured nearly 300 development deals in 2019 that are expected to result in more than 27,000 new jobs.
The fast-growing chain’s concept allows customers to stay in their cars. Also this week: Root & Bone, Gavel, People’s Revel Room, Gymboree Play & Music, Portrait Innovations and more.
Analysts have said that Dermira’s lead pipeline product, lebrikizumab, has the potential to be the best in class among a wave of similar antibodies to treat eczema.
